MX2017014806A - Conjugados oligonucleotido- peptido. - Google Patents
Conjugados oligonucleotido- peptido.Info
- Publication number
- MX2017014806A MX2017014806A MX2017014806A MX2017014806A MX2017014806A MX 2017014806 A MX2017014806 A MX 2017014806A MX 2017014806 A MX2017014806 A MX 2017014806A MX 2017014806 A MX2017014806 A MX 2017014806A MX 2017014806 A MX2017014806 A MX 2017014806A
- Authority
- MX
- Mexico
- Prior art keywords
- oligonucleotide conjugates
- peptide
- peptide oligonucleotide
- conjugates
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En la presente se proporcionan oligonucleótidos, péptidos y conjugados oligonucleótido-péptido; se proporcionan también en la presente métodos para tratar una enfermedad muscular, una infección viral o una infección bacteriana en un sujeto que lo necesita, que comprende administrar al sujeto oligonucleótidos, péptidos y conjugados oligonucleótido-péptido descritos en la presente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 | |
| PCT/US2016/033276 WO2016187425A1 (en) | 2015-05-19 | 2016-05-19 | Peptide oligonucleotide conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014806A true MX2017014806A (es) | 2018-05-11 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014806A MX2017014806A (es) | 2015-05-19 | 2016-05-19 | Conjugados oligonucleotido- peptido. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10675356B2 (es) |
| EP (2) | EP3297649B1 (es) |
| JP (2) | JP6954843B2 (es) |
| KR (2) | KR102644053B1 (es) |
| CN (2) | CN107921092B (es) |
| AU (1) | AU2016264471B2 (es) |
| BR (1) | BR112017024929A2 (es) |
| CA (1) | CA2986228A1 (es) |
| DK (1) | DK3297649T5 (es) |
| ES (1) | ES2964695T3 (es) |
| FI (1) | FI3297649T3 (es) |
| HK (1) | HK1252759A1 (es) |
| HR (1) | HRP20231431T1 (es) |
| IL (1) | IL255655B (es) |
| MA (1) | MA42134A (es) |
| MX (1) | MX2017014806A (es) |
| NZ (1) | NZ737757A (es) |
| WO (1) | WO2016187425A1 (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| KR20190027373A (ko) | 2016-07-05 | 2019-03-14 | 바이오마린 테크놀로지스 비.브이. | 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드 |
| CN110381980A (zh) * | 2017-01-06 | 2019-10-25 | 艾维迪提生物科学有限责任公司 | 核酸-多肽组合物以及诱导外显子跳读的方法 |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| CN118267396A (zh) | 2017-10-04 | 2024-07-02 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
| JP7356416B2 (ja) * | 2017-10-17 | 2023-10-04 | サレプタ セラピューティクス， インコーポレイテッド | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
| WO2019113393A1 (en) | 2017-12-06 | 2019-06-13 | Avidity Biosciences Llc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| TW202019442A (zh) * | 2018-07-30 | 2020-06-01 | 美商薩羅塔治療公司 | 用於反義遞送之三聚合肽 |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| MX2021001281A (es) | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías. |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2020247818A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Una amidites and uses thereof |
| CA3142283A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| US20230073008A1 (en) | 2019-12-26 | 2023-03-09 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid that induces skipping of exon 50 |
| US20230140736A1 (en) | 2020-02-28 | 2023-05-04 | Nippon Shinyaku Co., Ltd. | Antisense nucleic acid inducing skipping of exon 51 |
| CN115666589A (zh) | 2020-03-19 | 2023-01-31 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| EP4314298A1 (en) * | 2021-04-02 | 2024-02-07 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping |
| TW202307208A (zh) | 2021-06-23 | 2023-02-16 | 日商日本新藥股份有限公司 | 反義寡聚物之組合 |
| CA3225573A1 (en) | 2021-07-08 | 2023-01-12 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
| KR20240035502A (ko) | 2021-07-08 | 2024-03-15 | 니뽄 신야쿠 가부시키가이샤 | 신독성 경감제 |
| TW202308664A (zh) | 2021-07-08 | 2023-03-01 | 日商日本新藥股份有限公司 | 腎毒性減輕劑 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3226001A1 (en) | 2021-07-16 | 2023-01-19 | Anton Jan Van Zonneveld | Oligonucleotide for inhibiting quaking activity |
| IL311452A (en) | 2021-09-16 | 2024-05-01 | Avidity Biosciences Inc | Compositions and methods for the treatment of FSHD muscular dystrophy |
| TW202346589A (zh) | 2022-03-10 | 2023-12-01 | 日商日本新藥股份有限公司 | 抗病毒反義寡聚物 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| AU2023254846A1 (en) | 2022-04-15 | 2024-10-10 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| TW202400187A (zh) | 2022-05-06 | 2024-01-01 | 萊登大學醫院 萊登大學醫學中心 | 寡核苷酸 |
| WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| ATE171185T1 (de) | 1985-03-15 | 1998-10-15 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren |
| US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| WO2009064471A1 (en) | 2007-11-15 | 2009-05-22 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| WO2010048568A1 (en) * | 2008-10-23 | 2010-04-29 | Targeted Growth, Inc. | Modified photosynthetic microorganisms for producing triglycerides |
| CN112574988A (zh) | 2008-10-24 | 2021-03-30 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2547769B1 (en) * | 2009-11-25 | 2016-04-06 | ELITechGroup B.V. | Minor groove binder (mgb)-oligonucleotide mirna antagonists |
| ES2661813T3 (es) * | 2009-12-16 | 2018-04-04 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1 |
| JP5831455B2 (ja) | 2010-09-30 | 2015-12-09 | 日本新薬株式会社 | モルホリノ核酸誘導体 |
| JP2014513946A (ja) * | 2011-04-22 | 2014-06-19 | プロセンサ テクノロジーズ ビー．ブイ． | 筋強直性ジストロフィー１型（ｄｍ１）などのヒト遺伝性疾患の治療、遅延及び／又は予防のための新規の化合物 |
| CA2834128A1 (en) * | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US10066228B2 (en) * | 2011-11-30 | 2018-09-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| HUE038369T2 (hu) * | 2011-12-08 | 2018-10-29 | Sarepta Therapeutics Inc | Humán LMNA-t célzó oligonukleotid-analógok |
| JP6542662B2 (ja) * | 2012-03-20 | 2019-07-10 | サレプタ セラピューティクス， インコーポレイテッド | オリゴヌクレオチドアナログのボロン酸結合体 |
| EP3608407A1 (en) * | 2012-07-03 | 2020-02-12 | BioMarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| SG10201700751XA (en) * | 2012-09-25 | 2017-03-30 | Genzyme Corp | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| CN113633787A (zh) | 2013-03-15 | 2021-11-12 | 萨勒普塔医疗公司 | 改进的用于治疗肌营养不良的组合物 |
| EP3262056A4 (en) | 2015-02-27 | 2018-09-19 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2016
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active IP Right Grant
- 2016-05-19 BR BR112017024929-4A patent/BR112017024929A2/pt active Search and Examination
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/en active Active
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/en active Application Filing
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 MX MX2017014806A patent/MX2017014806A/es unknown
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 CA CA2986228A patent/CA2986228A1/en active Pending
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/en active Pending
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Application Filing
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2018
- 2018-09-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US20230310625A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ737757A (en) | Peptide oligonucleotide conjugates | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| PH12018501281A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| WO2013130703A3 (en) | Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use | |
| WO2017030823A3 (en) | Anti-tigit antibodies | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| NZ730563A (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| MX2018007307A (es) | Conjugados de peptidos y oligonucleotidos. | |
| WO2016172269A3 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
| WO2014140166A3 (en) | Vaccine | |
| UA117563C2 (uk) | Композиція для лікування або профілактики хвороби, асоційованої з інфекцією впл | |
| EA201792539A1 (ru) | Пептид-олигонуклеотидные конъюгаты | |
| WO2015132103A3 (en) | Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies | |
| MY178600A (en) | Antiviral composition against chikungunya virus |